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Abstract
Background—With improvements in therapy for inflammatory bowel disease (IBD) and
changes in the prevalence of obesity, the phenotype of Crohn's Disease (CD) is changing. These
changes may herald an increase in the incidence of non-alcoholic fatty liver disease (NAFLD) in
this population.
Methods—Over a ten-month period we identified seven patients with CD who required liver
biopsy for elevated liver function tests (LFTs), with an ultimate diagnosis of NAFLD. We
performed a retrospective chart review and literature search to identify relevant data on NAFLD
and CD. Specifically, we abstracted prior and current IBD-related medication exposures, disease
severity, and the presence of typical comorbidities associated with NAFLD.
Results—We describe seven patients with CD and biopsy-proven NAFLD. The majority of these
patients were overweight or obese, had quiescent CD, and were more likely to be receiving a
tumor necrosis factor-alpha inhibitor. Review of the literature produced a total of 29 articles
describing NAFLD in IBD patients, primarily restricted to historical autopsy and surgical series.
Limited contemporary studies highlight the rising prevalence of NAFLD in treated IBD
populations.
Conclusions—NAFLD is increasing in incidence and prevalence among the general population.
With improvements in therapy, NAFLD is likely increasing among the CD population as well.
When evaluating an IBD patient with abnormal LFTs, clinicians need to consider NAFLD.
NAFLD may impact IBD management in the future if therapeutic modalities are limited due to
elevated LFTs. Further, patients should be monitored for excessive weight gain and counseled
regarding healthy dietary and exercise habits.
Keywords
NAFLD; NASH; IBD; Crohn's Disease; Liver
Introduction
Patients with inflammatory bowel disease (IBD) are at risk of developing extra-intestinal
complications of disease, with primary sclerosing cholangitis, autoimmune hepatitis, and
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adverse treatment-related effects among the most frequently recognized conditions affecting
the hepatobiliary system.1 Non-alcoholic fatty liver disease (NAFLD), the most common
liver disorder in industrialized Western countries,2 is infrequently described in patients with
IBD. However, with improvements in treatment, in particular the advent of the tumor
necrosis factor-alpha (TNF-a) inhibitors and in conjunction with larger societal trends in
weight gain, the phenotype of IBD may be changing. Though traditionally viewed as
underweight and/or malnourished, IBD patients today are more likely to exhibit rates of
overweight and obesity on par with the general population.3-5 Consequently, these patients
are at risk of developing NAFLD. The hepatic inflammation and abnormal liver function
tests (LFTs) that often accompany a diagnosis of NAFLD may complicate treatment
decisions, influence pharmaceutical choices, and potentially predispose IBD patients to
develop cirrhosis. We describe seven patients with Crohn's disease (CD) and biopsy-proven
NAFLD, with the aim to describe potential risk factors including medication exposures,
clinical CD course, and related comorbidities, and to raise awareness of this infrequently
recognized complication that is likely increasing in incidence.
Materials and Methods
We identified a total of seven Crohn's disease patients evaluated at the University of North
Carolina between December 2009 and October 2010 for abnormal liver function tests, with
liver biopsy identifying non-alcoholic fatty liver disease. Patient characteristics, medical co-
morbidities, CD severity, current and past medications, and laboratory and pathologic results
were extracted from the medical record.
To identify existing literature, a Medline MeSH search was performed using the terms
“inflammatory bowel diseases” and “fatty liver.” Abstracts were searched to identify
relevant articles, with pertinent ones reviewed. Additional queries were performed using a
combination of MeSH terms including “Crohn disease,” “ulcerative colitis,” and “liver
diseases.” Individual bibliographies were hand-searched to identify additional associated
articles.
Results
A total of seven Crohn's disease patients with biopsy-proven NAFLD were identified. A
summary of the clinical characteristics of each patient is provided in Table 1. Five patients
were female; all were Caucasian. The mean age at time of NAFLD diagnosis was 35 (range:
23 to 49). Mean duration of CD was 11 years (range: 6 to 17). Obesity was defined in
standard fashion using the following body mass index (BMI) cut-points: normal BMI <25,
overweight BMI 25 – 29.9, obese BMI >30.6 Five of seven patients were obese (mean BMI:
35), one was overweight, and one was of normal body mass. Six of seven patients had
normal BMI at the time of IBD diagnosis; mean BMI increased by 7 kg/m2 from IBD onset
to time of NAFLD diagnosis. Four patients were receiving TNF-alpha inhibitors at the time
of biopsy, and 2 were receiving azathioprine (AZA) or 6-mercaptopurine (6-MP). All seven
patients were treated with corticosteroids in the course of their CD, though only a single
patient received them within the preceding 12 months. Four patients were in asymptomatic
remission from their CD at the time of liver biopsy.
A Medline MeSH search using terms “inflammatory bowel diseases,” “Crohn disease,”
“ulcerative colitis,” “fatty liver,” and “liver diseases” yielded 17 relevant manuscripts.
Review of individual bibliographies identified 12 related articles. A summary of the 29
included articles is provided in Table 2. Twenty-one articles were published prior to 1972,
with only 4 published in the last decade. The majority were case reports or case series
involving autopsy and/or surgical specimens. The prevalence of biopsy-proven NAFLD in
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these series was as high as 89%7, and was attributable to severe IBD and malnutrition.
Lower rates of NAFLD, on the order of 2% – 6%, were noted in less-ill populations.8-11
More recent studies, utilizing sonographic diagnosis, identified NAFLD in approximately
40% of IBD patients.12,13
Discussion
NAFLD and IBD in the medical literature
In this series, we highlight seven cases of biopsy-proven non-alcoholic fatty liver disease in
patients with underlying Crohn's disease. Though liver dysfunction is a recognized
complication of IBD,13,14 reports of NAFLD as the primary abnormality have been
infrequently described in the medical literature, and rarely in patients with treated, inactive
disease.
The first known description of hepatic steatosis in IBD was reported in 1873 by CH
Thomas, who described a young patient with “ulceration of the colon,” with autopsy
revealing “a much enlarged fatty liver.”15 Subsequent autopsy series reported a prevalence
of hepatic steatosis in 15% to 88% of IBD patients, representing the most common
pathologic abnormality. 16-26 Steatosis was presumed secondary to severe illness, with
malnutrition and hypoproteinemia primarily responsible.17 Further series examining liver
biopsies at the time of bowel resection supported this hypothesis.7,27-32 However, the
presence of hepatitis steatosis is less frequent when considering more diverse IBD
populations, with 2% to 6% prevalence in representative biopsy-based cross-sectional
studies.8-11 The inclusion of less-ill patients, compared to prior reports, may explain this
discrepancy. Notably, these studies preceded the obesity epidemic later observed in western
countries.
More recent studies utilizing ultrasound diagnosis suggest a higher prevalence of NAFLD.
In a large, single-center study of 511 patients with IBD, sonographic evidence of hepatic
steatosis was detected in 40% of CD patients, with severe steatosis in 12%. Though patients
with underlying obesity and/or metabolic disorders were excluded from this study, nearly
two-thirds of patients were receiving corticosteroids, a factor that may have contributed to
these findings.12 Similar rates of steatosis have been observed in other ultrasound-based
studies.13,33,34
Therefore, available evidence would suggest that NAFLD is not uncommon in IBD. The
majority of these studies, however, were conducted in patients with active, severe, even life-
threatening disease. Our series includes primarily treated, asymptomatic patients,
highlighting the occurrence of NAFLD in less-ill patients.
The rise of overweight and obesity in IBD
Traditionally, patients with inflammatory bowel disease have been viewed as underweight
or malnourished, particularly in the setting of active disease. In fact, weight deviation is one
of the eight components of the Crohn's Disease Acivity Index.35 This viewpoint was
supported by epidemiologic data from Scotland in the 1970s, where 28% and 57% of
juvenile CD patients fell below the 3rd percentiles for height and weight, respectively.36
These changes persisted into adulthood, irrespective of disease activity, with average weight
remaining below normal at a mean of 14 years follow-up. 37
However, more contemporary data suggest that the typical IBD phenotype may be evolving.
A subsequent study of IBD patients in Tayside, Scotland, found that rates of overweight and
obesity were 38% and 18%, respectively, equivalent to those in the general population.3
Similar findings were noted in a Netherland's cohort of CD patients in remission.4 A more
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recent cohort of pediatric patients in the United States under medical treatment for IBD
demonstrated a rate of overweight or obesity of 23.6%, comparable to the general
population.38
The patients in our series are no exception to this trend, six of which were either overweight
or obese. Obesity, along with diabetes mellitus, hypertension, and dyslipidemia, is a known
risk factor for NAFLD and patients with IBD are not exempt from this risk. Recognizing the
epidemic of overweight and obesity in modern society, with 68% of the adult population of
the United States affected,39 IBD patients may simply be mirroring larger trends. However,
other factors may be at play, including the direct and indirect role of pharmacotherapeutic
agents.
Pharmacotherapy: direct and indirect effects on hepatic steatosis
Medications used in the treatment of IBD carry a known risk of hepatoxicity.40 However,
NAFLD is an infrequently recognized complication of their use. Yet, specific agents may
directly contribute to hepatic steatosis, or indirectly induce weight gain, a principle factor in
its development.
Corticosteroids, a mainstay of IBD treatment, are known to produce weight gain and
steatosis.41,42 However, newer steroid-sparing therapies have reduced dependence on their
use. This is evident in our series, where only 1 patient was actively receiving a
corticosteroid, and the remaining 6 patients had been corticosteroid-free for a median of 3
years. The role of corticosteroids in the pathogenesis of NAFLD in IBD patients may be less
relevant today.
Methotrexate, which one patient in our series was actively receiving, has a well-recognized
risk of hepatotoxicity, particularly with prolonged administration.43 Observed histological
changes may overlap with those seen in NAFLD, including steatosis, inflammation, and
fibrosis.40 Further, concomitant obesity and diabetes mellitus may potentiate this risk.44 The
thiopurines (AZA and 6-MP), used by two patients in our series, have known liver toxicities,
including hepatocellular injury and cholestatic disease.13,45 However, hepatic steatosis is not
an identified risk.
The biologic agents, in particular the TNF-alpha inhibitors, have emerged as important
modalities in the treatment of moderate to severe Crohn's disease, allowing for induction and
maintenance of remission, and improved quality of life.46 Adverse hepatic effects associated
with their use include reactivation of viral hepatitis, direct hepatoxicity, and autoimmune
hepatitis.47 Furthermore, use of these agents may induce weight gain. Known also as
cachectin, TNF-alpha is an important mediator of muscle wasting and protein depletion in
states of inflammation and infection.48 Inhibition of its effects, then, could lead to changes
in body mass. In patients with rheumatologic disease, TNF-alpha inhibitors are linked to
increased body weight.49-52 This change was not observed with other agents, including
methotrexate.50,51
Few data are available regarding TNF-alpha-related weight changes in IBD patients. A
small, prospective study of infliximab use in 20 CD patients documented increase in body
weight at 4 weeks.53 Unpublished retrospective data from Isaacs, et al, examined infliximab
use in patients with Crohn's disease and rheumatoid arthritis (RA). Over the 4-year study
period, CD patients gained significantly more weight than RA patients (5kg vs. 1.2kg;
p=0.0049). The authors suggest that this difference may be explained by improvement in
mucosal function, leading to nutrient absorption and weight gain, perhaps more than a direct
medication effect.54 Additionally, treatment with TNF-alpha inhibitors may affect
circulating levels of leptin, a peptide that plays a central role in appetite control and insulin
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resistance, though evidence has been conflicting.53,55 Interestingly, the TNF-alpha inhibitors
have shown promise in the treatment of non-alcoholic steatohepatitis (NASH), with limited
evidence indicating a biochemical and histologic benefit.56-59 It is unclear how these
benefits might be outweighed by the risks associated with weight gain, at least in the
treatment of IBD patients.
In summary, treatment modalities for IBD have established adverse hepatic effects. Perhaps
most relevant to our case series, though, is their effectiveness in inducing and maintaining
remission, which may promote weight gain and contribute the development of fatty liver
disease.
Summary and Implications
Our case series highlights the existence of overweight, obesity, and non-alcoholic fatty liver
disease in patients under medical therapy for Crohn's disease. Though originally described in
patients with severe, active colitis, NAFLD is likely to increase in incidence among less-ill
IBD patients, particularly given rising rates of obesity, and the effectiveness of newer
treatment modalities in inducing remission. Obesity itself is a known risk factor for
increased anoperineal disease, earlier surgical interventions, and greater surgical
complications among Crohn's disease patients.60-62 Additionally, the abnormal LFTs that
frequently accompany NAFLD may make utilization of some drugs like AZA or MTX more
complicated. This, coupled with the potential morbidity and mortality related to NAFLD,
including cirrhosis and its complications, raises significant implications related to the health
of this population.
Conclusions
The phenotype of the inflammatory bowel disease patient is changing. With the emergence
of more effective pharmacotherapy, coupled with larger trends in society, IBD patients are
no longer underweight or malnourished. With rates of overweight and obesity now on par
with the general population, NAFLD – an important complication of weight gain – needs to
be recognized. When evaluating an IBD patient with abnormal liver function tests, clinicians
need to consider this entity. Further, patients should be monitored for excessive weight gain
and be counseled regarding healthy dietary and exercise habits.
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